Product image of Milgamma (Benfotiamine, Pyridoxine Hydrochloride) supplied by GNH India

Milgamma

Active Ingredient:
Benfotiamine, Pyridoxine Hydrochloride
Origin:
EU

Milgamma (Benfotiamine, Pyridoxine Hydrochloride)

Benfotiamine, the active ingredient in Milgamma, is a vitamin supplement presented as an oral dosage form for oral use. It is combined with pyridoxine hydrochloride (vitamin B6) to support carbohydrate metabolism and nerve function in adults, helping to reduce advanced glycation end‑products and assist amino‑acid metabolism.

GNH India supplies Milgamma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Manufacturer / TM Owner

Wörwag Pharma Gmbh & Co. Kg

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Milgamma, a combined benfotiamine and pyridoxine supplement, is used in conditions related to carbohydrate metabolism and nerve health.

  • Diabetic peripheral neuropathy: helps reduce nerve pain and improve sensory function.
  • Metabolic support in diabetes: assists in lowering formation of advanced glycation end‑products.
  • Vitamin B6 deficiency: contributes to normal amino‑acid metabolism and hemoglobin formation.

How It Works

  • Benfotiamine is a lipid‑soluble thiamine pro‑drug that is converted intracellularly to thiamine diphosphate, enhancing the activity of enzymes in the pentose‑phosphate pathway and reducing accumulation of advanced glycation end‑products. Pyridoxine (vitamin B6) serves as a co‑factor for enzymes involved in amino‑acid transamination, neurotransmitter synthesis and hemoglobin formation, together supporting metabolic and neural processes.

Side Effects

Milgamma is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Nausea: mild stomach upset reported by some users.
  • Headache: transient headache may appear.
  • Skin rash: mild, localized erythema.
  • Dizziness: occasional light‑headedness.
  • Gastrointestinal discomfort: mild abdominal cramping.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Hepatic enzyme elevation: rare increase in liver function tests.
  • Hematologic abnormalities: rare cases of blood dyscrasias.
  • Severe cutaneous reactions: such as Stevens‑Johnson syndrome.
  • Peripheral neuropathy worsening: very uncommon exacerbation of existing neuropathy.

Precautions & Warnings

Before using Milgamma, consider the following precautions.

  • Pregnancy: consult a healthcare professional before use.
  • Breastfeeding: use only if clearly needed and advised by a clinician.
  • Renal impairment: monitor kidney function and adjust use if required.
  • Hepatic impairment: exercise caution and monitor liver enzymes.
  • Concomitant medications: review all current drugs for potential interactions.
  • Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Milgamma may interact with other medicines; awareness of the type of interaction helps manage risk.

Major Interactions (Avoid)

  • Anticonvulsants (e.g., phenobarbital): may increase metabolism, reducing efficacy.
  • High‑dose vitamin B6 supplements: risk of cumulative toxicity.
  • Chemotherapy agents (e.g., vincristine): may exacerbate neurotoxicity.

Moderate Interactions (Monitor Closely)

  • Antidiabetic drugs: may enhance glucose‑lowering effect, requiring dose adjustment.
  • Warfarin: pyridoxine can affect INR, necessitating closer monitoring.
  • Alcohol: concurrent use may increase risk of neuropathy or liver stress.

Frequently Asked Questions

Milgamma is a nutritional supplement that combines benfotiamine and pyridoxine hydrochloride to support carbohydrate metabolism and nerve function. It is commonly used to help manage diabetic peripheral neuropathy, provide metabolic support in diabetes, and address vitamin B6 deficiency.

Benfotiamine is a lipid‑soluble form of thiamine that is converted inside cells to thiamine diphosphate, a co‑factor for enzymes in the pentose‑phosphate pathway. This enhances glucose metabolism and reduces the formation of harmful advanced glycation end‑products, which can protect nerves and blood vessels.

The appropriate dose of Milgamma is determined by the prescribing healthcare professional based on the individual’s condition, age, weight and other medications. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose on their own.

Safety data for Milgamma in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider to weigh potential benefits against any unknown risks.

To order Milgamma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Milgamma combines benfotiamine, a highly bioavailable thiamine pro‑drug, with pyridoxine hydrochloride, offering both carbohydrate‑metabolism support and vitamin B6 functions. Compared with standard thiamine or B6 tablets, the benfotiamine form may achieve higher intracellular levels, potentially providing greater protection against advanced glycation end‑products.

Milgamma should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool place helps maintain its stability and potency.

Milgamma is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. Swallow the dosage form whole with a glass of water and follow any specific instructions given by the healthcare professional.

Serious but rare risks include severe allergic reactions such as anaphylaxis, significant liver enzyme elevations, and rare hematologic abnormalities. If any signs of a serious reaction appear—such as difficulty breathing, rash, jaundice, or unexplained bruising—seek medical attention immediately.

Milgamma should be avoided by individuals with known hypersensitivity to benfotiamine, pyridoxine or any excipients in the formulation. Patients with severe renal or hepatic impairment should use it only under medical supervision, and it is not recommended for children unless specifically prescribed.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Benfotiamine, Pyridoxine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT